Skip to content

Cellectar Biosciences, Inc.: 10-Q filed 2025-11-13

What Cellectar Biosciences, Inc. reported in its quarterly report filed 2025-11-13 (fiscal Q3 2025): 30 published measures, 87 facts as tagged in accession 0001104659-25-110827.

This filing

Form
10-Q (quarterly report)
Filed
2025-11-13
Fiscal period
fiscal Q3 2025
Accession
0001104659-25-110827 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Cellectar Biosciences, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-09-3014,627,590USD
At 2024-12-3125,474,047USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-09-305,248,261USD
At 2024-12-319,797,343USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-09-307,997,306USD
At 2025-06-306,085,012USD
At 2025-03-318,253,389USD
At 2024-12-3114,294,681USD
At 2024-09-3015,164,940USD
At 2024-06-3012,380,973USD
At 2024-03-3112,501,095USD
At 2023-12-31-15,158,968USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-09-3012,554,289USD
At 2024-12-3123,288,607USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-4,443,877USD92
2025-01-01 to 2025-09-30-16,495,816USD273
2025-04-01 to 2025-06-30-5,447,911USD91
2025-01-01 to 2025-03-31-6,604,029USD90
2024-07-01 to 2024-09-30-14,664,719USD92
2024-01-01 to 2024-09-30-42,226,073USD274
2024-04-01 to 2024-06-30-919,371USD91
2024-01-01 to 2024-03-31-26,641,983USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-18,774,081USD273
2024-01-01 to 2024-09-30-36,669,523USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2024-01-01 to 2024-09-3042,909USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-09-308,039,763USD273
2024-01-01 to 2024-09-3061,410,815USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-42,909USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-09-30-263,838,280USD
At 2024-12-31-247,342,463USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-07-01 to 2025-09-303,162,040shares92
2025-01-01 to 2025-09-302,108,234shares273
2024-07-01 to 2024-09-301,311,197shares92
2024-01-01 to 2024-09-301,161,681shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-07-01 to 2025-09-303,162,040shares92
2025-01-01 to 2025-09-302,108,234shares273
2024-07-01 to 2024-09-301,326,474shares92
2024-01-01 to 2024-09-301,184,850shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-1.41USD/shares92
2025-01-01 to 2025-09-30-7.82USD/shares273
2024-07-01 to 2024-09-30-11.18USD/shares92
2024-01-01 to 2024-09-30-36.35USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-1.41USD/shares92
2025-01-01 to 2025-09-30-7.82USD/shares273
2024-07-01 to 2024-09-30-12.13USD/shares92
2024-01-01 to 2024-09-30-41.79USD/shares274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-09-30595,271USD
At 2024-12-31757,121USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-09-301,695,916USD273
2024-01-01 to 2024-09-302,787,666USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-4,850,696USD92
2025-01-01 to 2025-09-30-17,289,215USD273
2024-07-01 to 2024-09-30-13,327,677USD92
2024-01-01 to 2024-09-30-39,032,872USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-09-3013,621,698USD
At 2024-12-3124,250,272USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-09-304,912,366USD
At 2024-12-319,387,757USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-07-01 to 2025-09-302,523,305USD92
2025-01-01 to 2025-09-308,340,200USD273
2024-07-01 to 2024-09-305,493,496USD92
2024-01-01 to 2024-09-3019,927,019USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-09-303,192,040shares
At 2024-12-311,535,996shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-09-3012,554,289USD
At 2024-12-3123,288,607USD
At 2024-09-3034,263,371USD
At 2023-12-319,564,988USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-09-30271,314,776USD
At 2024-12-31261,116,351USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-09-30380,841USD
At 2024-12-31436,874USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-09-30433,000USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2025-09-3029,780USD
At 2024-12-3129,780USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-09-301,067,409USD
At 2024-12-31961,665USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-302,327,391USD92
2025-01-01 to 2025-09-308,949,015USD273
2024-07-01 to 2024-09-307,834,181USD92
2024-01-01 to 2024-09-3019,105,853USD274

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2025-01-01 to 2025-09-30164,136USD273
2024-01-01 to 2024-09-30223,082USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2025-07-01 to 2025-09-30406,819USD92
2025-01-01 to 2025-09-30793,399USD273
2024-07-01 to 2024-09-30-1,337,042USD92
2024-01-01 to 2024-09-30-3,193,201USD274

Inspect the source

Entity
Cellectar Biosciences, Inc. / CIK 0001279704
Captured
2026-09-20T07:48:31.991Z
SEC response SHA-256
44da00fed89c835867d9290b98319109f07ad849957763fd081353f99891a212

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001279704.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))